Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
What’s that, a win for CD47?
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
